Frost Radar™: Digital Biomanufacturing of Viral Vectors, 2025

Viral vectors are a critical part of gene therapies and genetic medicines, which are the cornerstone of precision medicines to cure rare diseases, cancers, and genetic disorders. Traditional bioprocessing, however, is tedious, less flexible, batch-based, and heavily manual; as a result, manufacturing processes involve high costs, scalability issues, and variability. Digital biomanufacturing represents a transformational shift in the development of viral vectors. The convergence of digital technologies and biomanufacturing makes the process more resilient, efficient, and adaptive. The demand for digital viral vector manufacturing is being driven by the intense competition in gene and cell therapies. Because of the one-time curative potential of these treatments, early adopters can gain the greatest patient share, while late entrants face a declining market. Because early launches can draw investors and gain a competitive advantage, speed and timeline adherence are crucial. Digital tools make the process more productive and scalable.

Frost & Sullivan analyzes numerous companies in an industry. Those selected for further analysis based on their leadership or other distinctions are benchmarked across 10 Growth and Innovation criteria to reveal their position on the Frost Radar. The publication presents competitive profiles of each company on the Frost Radar considering their strengths and the opportunities that best fit those strengths.